Merck Receives 2015 ENERGY STAR Sustained Excellence Award from US Environmental Protection Agency
Merck (MSD outside the US and Canada) has received an ENERGY STAR 2015 Partner of the Year —Sustained Excellence Award from the US Environmental Protection Agency (EPA) for its continued improvement of energy performance and leadership in energy management in both the pharmaceutical and industrial sectors.
Merck has been an ENERGY STAR partner since 1995 and recognized by the EPA for 10 consecutive years, two times as Partner of the Year and now an eighth time for Sustained Excellence.
“Merck's philosophy of being a responsible corporate citizen includes ensuring we manage our energy use efficiently,” said Rodney Freeman, vice president, global workplace & enterprise services, Merck. “Our partnership with ENERGY STAR helps us focus on our main goal of reducing energy consumption, and we are proud that we are using greener sources of energy and reducing greenhouse gas emissions.”
The award recognizes four Merck manufacturing sites that have achieved ENERGY STAR rankings in the top 25% of pharmaceutical plant energy performance nationwide: Arecibo, Puerto Rico; Cleveland, Tenn.; Las Piedras, Puerto Rico; and Elkhorn, Neb. Also achieving certification this year were office buildings in Whitehouse Station, NJ, as well as office buildings in Upper Gwynedd, Pa. and West Point, Pa. In addition, three sites were recognized for meeting the ENERGY STAR Challenge for Industry by reducing their energy intensity by 10% over a 5-year period. The sites recognized are Barceloneta, Puerto Rico; Friesoythe, Germany; and LaValle, France.
“Through their sustained participation with ENERGY STAR, Merck is helping Americans save money, save energy and do their part to reduce our nation’s greenhouse gas emissions that fuel climate change,” said EPA Administrator Gina McCarthy. “I applaud Merck for earning EPA’s highest ENERGY STAR award, the 2015 Partner of the Year — Sustained Excellence Award, demonstrating a strong commitment to energy efficiency and to preserving a healthy planet for future generations.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance